Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I

Väänänen, H. Kalervo; Vauhkonen, Matti; Helske, T; Kääriäinen, Ilpo; Rasmussen, Martin; H, Tunturi-Hihnala; Koskenpato, Jari; Sotka, M; Turunen, M; Sandström, Rolf; Ristikankare, Matti; Jussila, Airi; Sipponen, P

doi:10.1097/00042737-200308000-00009

Cited by 208 publications

(164 citation statements)

References 13 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…These results are similar with what has been reported in many other countries for example Sipponen et al (2002) [18] in Finland; Väänänen et al (2003) [19] in Finland; Pasechnikov et al (2004) [20] in Russia; Cavallaro et al (2004) [21] in Italy respectively reported the accuracy, sensitivity and specificity of the GastroPanel test as (91%:89%:93:%); (81%:79%:91%); (84%:79%:96%) and (96%:78%:98%). There was however, a significant difference in the diagnosis of atrophic antrum gastritis between the GastroPanel and histology (p < 0.01).…”

Section: Discussionsupporting

confidence: 93%

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection

Noah¹,

Assoumou²,

Fiacre³

et al. 2012

OJGas

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection

Noah¹,

Assoumou²,

Fiacre³

et al. 2012

OJGas

View full text Add to dashboard Cite

show abstract

“…Various studies in different populations demonstrated different levels of serum PGI, PGII and the PGI:II ratio (Table I) (19)(20)(21)(22)(23)(24). Serum PG concentrations measured in certain areas of Asia appear to be higher than those in Western countries.…”

Section: Introductionmentioning

confidence: 99%

Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus

et al. 2017

View full text Add to dashboard Cite

Abstract. There is a lack of non-invasive screening modalities to diagnose chronic atrophic gastritis (CAG) and intestinal metaplasia (IM). Thus, the aim of the present study was to determine the sensitivity and specificity of serum pepsinogen I (PGI), PGI:II, the PGI:II ratio and gastrin-17 (G-17) in diagnosing CAG and IM, and the correlations between these serum biomarkers and pre-malignant gastric lesions. A cross-sectional study of 72 patients (82% of the calculated sample size) who underwent oesophageal-gastro-duodenoscopy for dyspepsia was performed in the present study. The mean age of the participants was 56.2±16.2 years. Serum PGI:I, PGI:II, G-17 and Helicobacter pylori antibody levels were measured by enzyme-linked immunosorbent assay. Median levels of PGI:I, PGI:II, the PGI:II ratio and G-17 for were 129.9 µg/l, 10.3 µg/l, 14.7 and 4.4 pmol/l, respectively. Subjects with corpus CAG/IM exhibited a significantly lower PGI:II ratio (7.2) compared with the control group (15.7; P<0.001). Histological CAG and IM correlated well with the serum PGI:II ratio (r=-0.417; P<0.001). The cut-off value of the PGI:II ratio of ≤10.0 demonstrated high sensitivity (83.3%), specificity (77.9%) and area under the receiver operating characteristic curve of 0.902 in detecting the two conditions. However, the sensitivity was particularly low at a ratio of ≤3.0. The serum PGI:II ratio is a sensitive and specific marker to diagnose corpus CAG/IM, but at a high cut-off value. This ratio may potentially be used as an outpatient, non-invasive biomarker for detecting corpus CAG/IM.

show abstract

“…thus, a full understanding of the molecular mechanism of carcinogenesis and identification of biomarkers for the early diagnosis and effective treatment of human GC are crucial. Although several serum biomarkers have been researched as new invasive tools for screening GC (6)(7)(8)(9), these serum tests are not available as screening or surveillance tests due to their low specificity and sensitivity (9). Biomarkers derived from tumor tissues may provide higher sensitivity and specificity than those from serum (10), yet tissue specimens must be obtained by invasive means involving endoscopy and biopsy.…”

Section: Introductionmentioning

confidence: 99%

Tissue metabolomic fingerprinting reveals metabolic disorders associated with human gastric cancer morbidity

Wang²,

Liu³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. the principal way to improve the outcome of gastric cancer (GC) is to predict carcinogenesis and metastasis at an early stage. the aims of the present study were to test the hypothesis that distinct metabolic profiles are reflected in GC tissues and to further explore potential biomarkers for GC diagnosis. Gas chromatography/mass spectrometry (GC/Ms) was utilized to analyze tissue metabolites from 30 GC patients. A diagnostic model for GC was constructed using orthogonal partial least squares discriminant analysis (OpLs-DA), and the metabolomic data were analyzed using the non-parametric Wilcoxon rank sum test to identify the metabolic tissue biomarkers for GC. Over 100 signals were routinely detected in one single total ion current (tIC) chromatogram, and the OPLS-DA model generated from the metabolic profile of the tissues adequately discriminated the GC tissues from the normal mucosae. Among the low-molecular-weight endogenous metabolites, a total of 41 compounds, such as amino acids, organic acids, carbohydrates, fatty acids and steroids, were detected, and 15 differential metabolites were identified with significant difference (p<0.05). A total of 20 variables were noted which contributed to a great extent in the discriminating OpLs-DA model (VIp value >1.0), among which 12 metabolites were identified using both VIP values (VIP >1) and the Wilcoxon test (p<0.05). In conclusion, the identification of the metabolites associated with GC morbidity potentially revealed perturbations of glycolysis, fatty acid β-oxidation, cholesterol and amino acid metabolism. these results suggest that tissue metabolic profiles have great potential in detecting GC and may aid in understanding its underlying mechanisms.

show abstract

Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I

Abstract: The diagnosis of atrophic gastritis obtained with the blood test panel of S-G-17, S-PGI and H. pylori antibodies is in good agreement with the endoscopic and biopsy findings. The panel is a tool for non-endoscopic diagnosis and screening of atrophic gastritis.

Cited by 208 publications

References 13 publications

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection

Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus

Tissue metabolomic fingerprinting reveals metabolic disorders associated with human gastric cancer morbidity

Contact Info

Product

Resources

About

Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I

Abstract: The diagnosis of atrophic gastritis obtained with the blood test panel of S-G-17, S-PGI and H. pylori antibodies is in good agreement with the endoscopic and biopsy findings. The panel is a tool for non-endoscopic diagnosis and screening of atrophic gastritis.

Cited by 208 publications

References 13 publications

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and &lt;i&gt;Helicobacter pylori&lt;/i&gt; infection

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and &lt;i&gt;Helicobacter pylori&lt;/i&gt; infection

Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus

Tissue metabolomic fingerprinting reveals metabolic disorders associated with human gastric cancer morbidity

Contact Info

Product

Resources

About

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection

Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection